The Catalog was jointly organized and evaluated by five government bodies: the Industry and Information Technology Ddepartment of Jiangsu ,the Jiangsu Provincial Department of Science and Technology, the Jiangsu Commission of Health, the Jiangsu Healthcare Security Administration, and the Jiangsu Medical Products Administration. Focusing on high-quality pharmaceutical products approved after March 2021 that have demonstrated technical advancement and clinical application value, the Catalog is designed to facilitate access of superior-quality drugs into hospital formularies, accelerate the translation of innovative outcomes into clinical practice, and ultimately benefit a broader patient population.

JumpCan Pharmaceutical is the first domestic enterprise to receive regulatory approval for a dry suspension formulation of fexofenadine. The dry suspension formulation offers convenient portability, excellent stability, and ease of administration, making it particularly well-suited for pediatric patients and elderly patients with swallowing difficulties. It helps improve palatability and patient acceptability. Minfeile (Fexofenadine Hydrochloride for Suspension) is indicated for the relief of symptoms associated with seasonal allergic rhinitis and for the alleviation of skin symptoms of chronic idiopathic urticaria in patients aged 6 months and older, including both children and adults. Precise dosing regimens are available for each age group. In 2024, the product was included in the National Medical Insurance Drug Catalog, extending its benefits to a wider patient population.